31-Aug-2026
Major Investor Makes Dramatic Exit From Relay Therapeutics
TipRanks (Fri, 28-Aug 10:09 PM ET)
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Globe Newswire (Thu, 30-Jul 4:05 PM ET)
Relay Therapeutics’ $275 Million Offering: What the Major Capital Raise Signals for RLAY
Market Chameleon (Thu, 21-May 6:32 AM ET)
Relay Therapeutics' $275 Million Offering Bolsters Pipeline Ambitions—Key Details for Investors
Market Chameleon (Thu, 21-May 4:15 AM ET)
Market Chameleon (Mon, 16-Mar 3:53 AM ET)
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Relay Therapeutics trades on the NASDAQ stock market under the symbol RLAY.
As of August 31, 2026, RLAY stock price declined to $18.38 with 3,278,352 million shares trading.
RLAY has a beta of 1.55, meaning it tends to be more sensitive to market movements. RLAY has a correlation of 0.09 to the broad based SPY ETF.
RLAY has a market cap of $4.03 billion. This is considered a Mid Cap stock.
Last quarter Relay Therapeutics reported $350,000 in Revenue and -$.41 earnings per share. This fell short of revenue expectation by $-678,000 and missed earnings estimates by -$.01.
In the last 3 years, RLAY traded as high as $21.27 and as low as $1.78.
The top ETF exchange traded funds that RLAY belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.
RLAY has outperformed the market in the last year with a return of +398.1%, while the SPY ETF gained +19.4%. In the last 3 month period, RLAY beat the market returning +32.2%, while SPY returned +1.9%. However, in the most recent 2 weeks RLAY has underperformed the stock market by returning -7.5%, while SPY returned -1.2%.
RLAY support price is $18.15 and resistance is $19.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLAY shares will trade within this expected range on the day.
